Hector Ávila
Director General
Cecyc Pharma
Diego Avila
Diego Ávila
Commercial Director
Cecyc Pharma
View from the Top

Future Trends in Mexico’s Clinical Research

Wed, 09/05/2018 - 16:46

Q: How does Cecyc Pharma differentiate itself from other CROs in the country?

HA: In 2013, the mandatory change for bioequivalence studies in generic drugs reinforced the role of Cecyc Pharma’s participation in the development of generic drugs. We have the best infrastructure and the best specialists to evolve alongside the market, which requires that we guarantee that our customers receive an added value from our services.

Our core business is bioequivalence studies, clinical and analytics services and in-vitro tests. This makes us a different CRO not only because of our vast portfolio but also because of our understanding of all the processes and requirements of the pharmaceutical sector. We break the traditional CRO mold and provide support to our clients before, during and after the development of the generic drug. DA: Cecyc Pharma offers a comprehensive service to its clients: we offer support in the acquisition of raw materials, for research on bioequivalent medicines, with the compilation of regulatory information and, if necessary, we accompany the client to his meetings with regulatory authorities such as COFEPRIS.

Q: What trends do you think will affect the clinical research market in the short term?

HA: Bioequivalence studies have become a necessary parameter to improve the competitiveness of generic medicines. Also, the increase in R&D biotechnological studies and phase I-II clinical research studies are transforming the pharmaceutical industry in Mexico. Cecyc Pharma believes there will be more clinical research developments in central areas such as diabetes, oncology, cardiology, geriatrics and chronic-degenerative diseases.

Q: What regulatory changes are necessary to truly turn Mexico into a clinical trials hub?

HA: Mexico must increase the number of professionals dedicated to research and encourage more people to specialize in the pharmaceutical sector. We need a greater formalization of R&D studies and the regulatory authorities must strengthen the industry’s clinical and analytical capacities. This could improve Mexico’s competitiveness on an international scale.

DA: More pharmaceutical industry players should open up to dialogue and collaborate more closely with CROs like Cecyc Pharma as a greater recognition of CROs can improve the performance of companies, the efficiency of drugs and strengthen the recognition that COFEPRIS has with its international regulatory counterparts.

Q: How has your research portfolio changed during the year? What role do the most common chronic diseases play in Cecyc Pharma’s research agenda?

HA: We are always aware of the expiration dates of patents on brand drugs to advance in the development of molecules for generic drugs. Our research portfolio changes as the pharma industry changes, so we must adapt quickly and create clinical research protocols that meet market demands.

DA: Our experience is the key to our services. Cecyc Pharma has more than 200 methods of analysis and 60 researchers to maintain constant participation in the pharmaceutical industry.

Q: How will the relocation of Cecyc Pharma in Morelos translate into better opportunities?

HA: The state of Morelos has the highest number of researchers per capita in the country. Therefore, if we can combine the offerings of a scientific and technological park like INOVACYT and a clinical research company like ours, we will boost R&D studies in Mexico. Also, the focus on clinical research studies is growing in Morelos because it is the only state with a Ministry of Innovation, Science and Technology (SICYT).